Device Management in HFpEF and HFmrEF: Insights From the REDUCE LAP-HF II Trial
Published: 24 January 2022
-
Views:
5417
-
Likes:
7
Overview
Full programme
Latent Pulmonary Vascular Disease and its Impact on Atrial Shunt Treatment: A Roundtable Discussion
Overview
HF with preserved ejection fraction (HFpEF) remains an unmet need, however new therapeutic strategies are emerging to improve quality of life and clinical outcomes. Although medical therapy is the cornerstone of treatment for individuals with EF ≥40%, there is a considerable need for approaches that extend these benefits to individuals who remain symptomatic following medical therapy.
The following videos aim to educate physicians in the changing landscape of the device management of HFpEF.
Learning Objectives
- Explain the clinical rationale behind an atrial shunt in HFpEF
- Recall overall and pre-specified sub-group results from the REDUCE LAP-HF II trial
- Describe the clinical features of likely responders and non-responders to an atrial shunt
- Identify which HFpEF patients are likely to benefit from the use of an atrial shunt
- Discuss the utility of cardiac interventions for the future treatment of HFpEF
Target Audience
- Heart Failure Specialists
- General Cardiologists
More from this programme
Part 1
Data Presentation
Part 2
Roundtable Discussion
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Personal History6
Professor Andrew Justin Stewart Coats was born in Melbourne, Australia on 1 February 1958. His father was a Professor of Resuscitation who first described essential fatty acids.
He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor.
Academic History
Professor Coats attended Melbourne Grammar School and studied at Oxford and Cambridge.9 He has higher doctorates from Oxford (DM) and Imperial (DSc.) and an MBA from London Business School.1
He obtained a Bachelor of Arts in 1979, a Bachelor of Medicine and Surgery in 1981, a Master of Arts in 1982, a PhD in Management in 1989, became a Doctor of Sciences in 1999 and completed a further Masters in Business Administration in 2001.
Gerd Hasenfuß
Professor of Internal Medicine, Director of the Department of Cardiology and Pulmonology
Prof Gerd Hasenfuß is a Professor of Internal Medicine, Director of the Department of Cardiology and Pulmonology, Georg-August-Universität Göttingen; Chairman of the Heart Center and the Herzforschungszentrum Göttingen; Head of Internal Medicine, Clinic and Rehabilitation Center Lippoldsberg gGmbH.
Sanjiv Shah
Professor
Dr Sanjiv Shah’s clinical expertise and research program are focused on HFpEF and in 2007, Dr Shah started the first dedicated HFpEF program in the world at Northwestern University.
His research, which spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity and systemic nature of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF.
He is an internationally recognised leading authority on HFpEF and routinely lectures at international cardiology meetings, continuing medical education meetings, and academic institutions.